Joana Vieira Barbosa, Michelle Lai – 31 October 2020 – Nonalcoholic fatty liver disease (NAFLD) is a major public health problem worldwide and the most common chronic liver disease. NAFLD currently affects approximately one in every four people in the United States, and its global burden is expected to rise in the next decades. Despite being a prevalent disease in the general population, only a minority of patients with NAFLD will develop nonalcoholic steatohepatitis (NASH) with advanced liver fibrosis (stage 3‐4 fibrosis) and liver‐related complications.

Juanjuan Zhao, Fengyun Chu, Hualin Xu, Mengmeng Guo, Shan Shan, Wen Zheng, Yijing Tao, Ya Zhou, Yan Hu, Chao Chen, Tao Ren, Lin Xu – 30 October 2020

Michelle T. Long, Xiaoyu Zhang, Hanfei Xu, Ching‐Ti Liu, Kathleen E. Corey, Raymond T. Chung, Rohit Loomba, Emelia J. Benjamin – 30 October 2020

Jean C. Emond – 30 October 2020

Nadim Mahmud, David S. Goldberg, David E. Kaplan, Marina Serper – 29 October 2020

Eric Kauffman‐Ortega, Jesus Ruiz‐Manriquez, Antonio Olivas‐Martinez, Alejandro Campos‐Murguia, Ernesto Marquez‐Guillen, Nayelli Flores‐Garcia, Mario Vilatoba, Alan Contreras‐Saldivar, Ignacio García‐Juárez – 28 October 2020

Angeline Yasodhara, Victor Dong, Amirhossein Azhie, Anna Goldenberg, Mamatha Bhat – 28 October 2020 – Diabetes mellitus (DM) significantly impacts long‐term survival after liver transplantation (LT). We identified survival factors for LT recipients who had DM to inform preventive care using machine‐learning analysis. We analyzed risk factors for mortality in patients from across the United States using the Scientific Registry of Transplant Recipients (SRTR). Patients had undergone LT from 1987 to 2019, with a follow‐up of 6.47 years (standard deviation [SD] 5.95).

Sven M. Francque – 27 October 2020

Daisuke Noguchi, Naohisa Kuriyama, Taemi Hibi, Koki Maeda, Toru Shinkai, Kazuyuki Gyoten, Aoi Hayasaki, Takehiro Fujii, Yusuke Iizawa, Akihiro Tanemura, Yasuhiro Murata, Masashi Kishiwada, Hiroyuki Sakurai, Shugo Mizuno – 27 October 2020 – Thrombin is a key player in the coagulation cascade, and it is attracting much attention as a promotor of cellular injured signaling. In ischemia/reperfusion injury (IRI), which is a severe complication of liver transplantation, thrombin may also promote tissue damage.

Elizabeth M. Brunt, David E. Kleiner, Danielle H. Carpenter, Mary Rinella, Stephen A. Harrison, Rohit Loomba, Zobair Younossi, Brent A. Neuschwander‐Tetri, Arun J. Sanyal, for the American Association for the Study of Liver Diseases NASH Task Force – 27 October 2020 – The role of liver biopsy in NASH has evolved along with the increased recognition of the significance of this disease, and the unmet medical need it presents. Drug development and clinical trials are rapidly growing, as are noninvasive tests for markers of steatosis, inflammation, injury, and fibrosis.